Antag begins trial of AT-7687, a GIPR antagonist designed to address key gaps in obesity treatment

Antag Therapeutics has initiated its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist. AT-7687 is designed to offer a new approach to obesity treatment by targeting the GIPR, a mechanism with strong genetic and clinical validation for its potential to improve weight loss efficacy and tolerability of incretin-based therapies.

According to the company, AT-7687 is uniquely designed to address these challenges by offering a targeted, well-tolerated obesity treatment, either as a monotherapy or in combination with other treatments such as the GLP-1 and amylin-based therapies. Moreover, AT-7687 has the potential to deliver additional cardiometabolic benefits such as improved glycemic control and body composition.

The Phase 1a trial is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of AT-7687. It will be conducted in healthy lean and healthy subjects living with obesity, with topline results expected in Q4 2025.

Following this study, the Company plans to investigate AT-7687 as a combination therapy in patients treated with a GLP-1 receptor agonist, with the study expected to commence at the end of 2025.

“The initiation of this Phase 1 trial represents a pivotal milestone for Antag and in advancing the chronic weight management paradigm for people living with obesity. While GLP-1-based therapies have transformed treatment options, many patients continue to face challenges with tolerability and long-term adherence,” said Jörg Möller, Chief Executive Officer of Antag Therapeutics. “AT-7687 is uniquely designed to address these gaps, with remarkable potential both as a standalone therapy and as a powerful complement that may be flexibly combined with existing and future treatment options for more individualised therapy. By leveraging a novel mechanism of action, AT-7687 aims to deliver not only sustained and healthier weight loss, but comprehensive long-term benefits across a range of indications.”

AT-7687 has demonstrated potential in preclinical models, achieving a profound body weight reduction in non-human primates over six weeks. Notably, when combined with a GLP-1 agonist, its weight loss effects were enhanced, suggesting a synergistic benefit for patients requiring combination therapy. Additionally, AT-7687 has shown excellent tolerability, with substantially lower gastrointestinal side effects than existing therapies, potentially improving long-term adherence and treatment outcomes.